Halozyme Therapeutics (HALO) EPS (Weighted Average and Diluted) Growth (3y) (2014 - 2026)
Halozyme Therapeutics (HALO) EPS (Weighted Average and Diluted) Growth (3y) (2014 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EPS (Weighted Avg. Diluted) Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
814,307.08 Bn |
814,307.05 Bn |
- |
- |
| 2 |
Belite Bio |
55,320.00 Bn |
55,320.00 Bn |
- |
59.54% |
| 3 |
Quantum Biopharma |
17,149.72 Bn |
17,149.72 Bn |
- |
22,777.33% |
| 4 |
Legend Biotech |
3,590.00 Bn |
3,589.71 Bn |
242.10 Mn |
1,857.10% |
| 5 |
Akari Therapeutics |
1,650.72 Bn |
1,650.72 Bn |
- |
41.33% |
| 6 |
Evaxion A |
1,522.09 Bn |
1,522.07 Bn |
- |
- |
| 7 |
Psyence Biomedical |
229.39 Bn |
229.38 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.09 Bn |
105.85 Bn |
2.59 Bn |
14.33% |
| 9 |
Abivax |
90.15 Bn |
90.15 Bn |
- |
- |
| 10 |
Halozyme Therapeutics |
8.24 Bn |
7.92 Bn |
297.47 Mn |
61.43% |
| Date | Value |
|---|
| Mar 31, 2026 |
61.43% |
| Dec 31, 2025 |
-67.11% |
| Sep 30, 2025 |
48.12% |
| Jun 30, 2025 |
102.57% |
| Mar 31, 2025 |
29.32% |
| Dec 31, 2024 |
32.08% |
| Sep 30, 2024 |
-10.81% |
| Jun 30, 2024 |
5.11% |
| Mar 31, 2024 |
46.71% |
| Dec 31, 2023 |
9.14% |
| Sep 30, 2023 |
34.63% |
| Jun 30, 2023 |
43.38% |
| Mar 31, 2023 |
109.92% |
| Dec 31, 2022 |
55.36% |
| Sep 30, 2022 |
66.17% |
| Jun 30, 2022 |
53.26% |
| Mar 31, 2022 |
250.34% |
| Dec 31, 2021 |
263.42% |
| Sep 30, 2021 |
113.92% |
| Jun 30, 2021 |
80.44% |
